Cardiology · Medical Literature
[Comment] Combination antithrombotic therapy in atrial fibrillation after coronary interventions: shorter duration, more safety?
Abstract
Patients with atrial fibrillation are at high risk of stroke and bleeding, and as coronary artery disease commonly coexists, such patients can present with chronic coronary syndrome or acute coronary syndromes including unstable angina, often requiring percutaneous coronary intervention (PCI) with coronary stenting.1 In such patients with atrial fibrillation, there are four factors that have to be carefully balanced: stroke prevention with the use of oral anticoagulant (nowadays usually a direct oral anticoagulant [DOAC]), given the high thromboembolic risk; antiplatelets for reducing recurrent cardiac ischaemia, especially in association with unstable angina; antiplatelets to reduce stent thrombosis; and bleeding risks when oral anticoagulant is combined with one or more antiplatelets, with the risk increasing with one and even greater with two antiplatelets.
Clinical relevance
In patients with atrial fibrillation who have undergone PCI with coronary stenting, does 1 month of dual antithrombotic therapy (DOAC plus P2Y12 inhibitor) followed by DOAC monotherapy maintain thromboembolic efficacy while improving bleeding safety compared with 12 months of dual therapy? __SNAPSHOT__ {"studyDesign":"Editorial Comment accompanying a primary RCT (OPTIMA-AF: multicentre, open-label, hybrid non-inferiority and superiority randomised controlled trial). The source article is a Lancet Comment/Editorial, not a primary research report.","setting":"Japan; 75 hospital sites (primary OPTIMA-AF trial). The Comment authors are based at the Liverpool Centre for Cardiovascular Science (UK) and Medical University of Bialystok (Poland).","sampleSize":"n=1,088 (OPTIMA-AF trial, as referenced in the accompanying Comment); allocation not reported in Comment abstract.","population":"Adults with non-valvular atrial fibrillation and coronary artery disease (predominantly chronic coronary syndrome, including stable and unstable angina, and silent myocardial ischemia, but not acute MI) undergoing PCI with everolimus-eluting stent implantation. Mean age approximately 75 years; approximately 79% male; exclusively East Asian (Japanese) population.","intervention":"1 month of dual antithrombotic therapy (DOAC plus P2Y12 inhibitor, with optional aspirin up to 1 month at physician discretion) followed by DOAC monotherapy for the remainder of the 12-month period.","comparator":"12 months of dual antithrombotic therapy (DOAC plus P2Y12 inhibitor) followed by DOAC monotherapy.","primaryOutcome":"Efficacy: composite of all-cause death, myocardial infarction, stroke, and stent thrombosis at 12 months (non-inferiority). Safety: ISTH major or clinically relevant non-major bleeding at 12 months (superiority).","followUp":"12 months","fundingSource":"Not reported in the Comment abstract. OPTIMA-AF was an investigator-initiated trial; Sotomi reported speaker/research fees from multiple industry sponsors."}
Key findings
Based on the OPTIMA-AF trial results cited in this Lancet Comment: The primary efficacy endpoint (death or thromboembolic events at 12 months) occurred in 4.5% of the 1-month dual therapy group versus 5.4% of the 12-month group (HR 1.20; 95% CI 0.70–2.07; absolute difference 0.9% [calculated favoring 12-month arm]; non-inferiority p=0.002, meeting the pre-specified non-inferiority margin of 5%). Superiority for the efficacy endpoint was not demonstrated. For the primary safety endpoint, ISTH major or clinically relevant non-major bleeding occurred in 4.8% (1-month) versus 9.5% (12-month) (HR 0.50; 95% CI 0.31–0.80; absolute risk reduction 4.7% [calculated]; p=0.004), representing a statistically significant and potentially clinically important reduction in bleeding with shorter dual therapy. NNT to prevent one bleeding event = approximately 21 (calculated). The Comment contextualises these findings within the four-factor framework clinicians must balance in AF patients undergoing PCI: stroke prevention via DOAC, antiplatelet therapy for ischaemic event and stent thrombosis prevention, and the incremental bleeding risk of adding one or two antiplatelet agents to anticoagulation. No novel efficacy or safety data are presented in the Comment itself beyond those derived from OPTIMA-AF.
Practice implications
This Lancet Comment by Lip and Kuzma frames the OPTIMA-AF RCT results within the established clinical tension of managing AF patients undergoing PCI. The trial established that 1-month dual antithrombotic therapy was non-inferior to 12-month dual therapy for thromboembolic outcomes and superior for bleeding reduction in a Japanese cohort undergoing elective or semi-elective PCI predominantly for chronic coronary syndrome. What the study did NOT establish: (1) efficacy and safety in patients with acute MI or high-thrombotic-risk ACS, who were largely excluded; (2) generalisability to non-East-Asian populations, given known racial differences in ischaemic and bleeding risk profiles; (3) whether 1–3 months may be preferable to exactly 1 month; (4) outcomes beyond 12 months. The event rate was approximately half of that planned at study design, which underpowered the efficacy analysis and mandates cautious interpretation of the non-inferiority conclusion. The near-universal use of intravascular imaging guidance (IVUS/OCT) during PCI may limit external validity in settings where angiography-guided PCI predominates. Clinicians should note that the bleeding benefit (ARR 4.7%) substantially exceeds the efficacy trade-off (absolute difference 0.9%), suggesting a favourable net clinical benefit in appropriately selected patients. However, this benefit should not be extrapolated to ACS-PCI patients or those at high stent thrombosis risk. Only an abstract of the Comment is publicly available; full editorial commentary and nuances are not accessible for review. __LIMITATIONS__ 1. This article is a published Comment/Editorial, not a primary research report; its clinical conclusions depend entirely on the OPTIMA-AF trial it accompanies. 2. Open-label trial design (OPTIMA-AF) introduces potential ascertainment bias for both efficacy and safety endpoints. 3. Observed event rate was approximately 50% of the planned rate, substantially underpowering the efficacy non-inferiority analysis and raising the risk of a false non-inferiority conclusion (type II error). 4. Exclusively Japanese (East Asian) population limits generalisability; East Asian patients have a distinct ischaemic-bleeding risk profile (the 'East Asian paradox') compared with Western cohorts. 5. Near-universal intravascular imaging guidance during PCI is not standard practice globally, potentially improving stent optimisation outcomes and reducing stent thrombosis risk, limiting applicability to angiography-guided centres. 6. ACS patients (particularly those with acute MI) were excluded, limiting guidance for the highest-risk PCI population. 7. Non-inferiority margin of 5% is relatively wide and carries risk of 'biocreep.' 8. Only 12-month follow-up; longer-term ischaemic outcomes after DOAC monotherapy are unknown. 9. Sponsor relationships of the primary trial investigators (multiple industry ties) warrant consideration. 10. Comment format precludes independent meta-analytic synthesis or adjustment for confounders. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ In AF patients undergoing elective PCI for chronic coronary syndrome, the OPTIMA-AF trial—contextualised by this Lancet Comment—suggests that 1-month DOAC plus P2Y12 inhibitor therapy followed by DOAC monotherapy is non-inferior to 12-month dual therapy for thromboembolic events and significantly reduces clinically relevant bleeding. These results are hypothesis-generating and most applicable to stable CAD patients in imaging-guided PCI settings, and should not yet be extrapolated to ACS-PCI patients or non-East-Asian populations until confirmatory evidence from broader, adequately powered trials is available.